Your Specialist for Allergy & Asthma Testing
and Finding Relief from Allergies and Asthma​​

San Diego Allergy Asthma & Immunology Consultants

Allergist-Immunologist M.D.


Feigenbaum BA, Stevenson DD, Simon RA.  Respiratory Succinate Sensitivity That Does Not Cross-react In An Aspirin Sensitive Asthmatic.  Ann Allergy, 1994; 72:94.  Feigenbaum BA, Simon RA, Stevenson DD.  Aspirin Intolerance. (Letter) Ann Allergy, 1994; 73:455-56.  

Feigenbaum BA, Stevenson DD, Simon RA.  Lack of Cross-Sensitivity To IV Hydrocortisone in Aspirin-Sensitive Subjects With Asthma. J Allergy Clin Immunol 1994; 93:242.

Feigenbaum BA, Stevenson DD, Simon RA.  Hydrocortisone Sodium Succinate Does Not Cross-react With Aspirin in Aspirin Sensitive Asthmatics. J Allergy Clin Immunol 1995; 96:545-8.

Feigenbaum BA.  Insect-sting challenges-all risk and no benefit? (Letter) J Allergy Clin Immunol 1995; 96:704-705.Feigenbaum BA, Simon RA. Remission of Steroid Dependent Asthma Following Fundoplication for Publications  (continued)Asymptomatic Reflux. J Allergy Clin Immunol, 1995; 95:202.

​Feigenbaum BA, Simon RA. A Case of Vocal Cord Dysfunction Mimicking Asthma. Ann Allergy, 1995; 74:92.

Feigenbaum, BA.  Self-reported, doctor-diagnosed 'asthma' is not necessarily asthma;  78.9% of these 'asthma' cases were atopic. (Correspondence) J Allergy Clin Immunol 2008;121:1291.

Feigenbaum BA.  Fractional exhaled nitric oxide in subjects with atopic asthma: Correct Definitions of the Terms Atopy and Asthma. (Correspondence) Ann Allergy Asthma Immunol 2008; 101; 110.

Miro K, Feigenbaum BA, Mathew A, Weinfeld JN.  Successful Oxaliplatin Desensitization After Unsuccessful Infusion Using A Hypersensitivity Protocol. (Abstract) Ann Allergy Asthma Immunol 2010; 105; A27.

Mathew A, Feigenbaum BA, Miro K, Weinfeld JN.  Iatrogenic Hypogammaglobulinemia Resembling Common Variable Immunodeficiency.  (Abstract)  Ann Allergy Asthma Immunol 2010; 105; A101.

Sutaria M, Miro K, Kister I, Herbert J, Mathew A, Feigenbaum BA.  Special Considerations for Rapid Drug Desensitization with Natalizumab. (Abstract)  J Allergy Clin Immunol, 2011; 127:Supp, AB196.

Mathew A, Ballas M, Gorsky M, Miro K, Feigenbaum BA.  Rapid Desensitization Does Not Prevent "Idiosyncratic" Reaction with Fever to Oxaliplatin. (Abstract)  J Allergy Clin Immunol, 2011; 127: Supplement, AB195.

Romanos-Sirakis, E, Feigenbaum BA. Immediate Hypersensitivity Reaction and Successful Rapid Desensitization to Rituximab Followed by Serum Sickness in a 4 Year Old.  (Abstract)  J Allergy Clin Immunol, 2011; 127: Supp, AB198.

​Lieberman SM, Jacobs JB, Lebowitz RA, Fitzgerald MB, Crawford J, Feigenbaum BA.Measurement of Mycotoxins in Patients with Chronic Rhinosinusitis. Otolaryngol Head Neck Surg, 2011;145(2): 327–29
1983-1989           Boston University School of Medicine
(6 Year Medical Program -- Combined BA/MD 09/1983 to 05/21/89)

1989-1992          Internal Medicine Residency, (Scripps) Mercy Hospital, San Diego CA
1992-1993          Chief Resident, (Scripps) Mercy Hospital, San Diego CA
1993-1995          Clinical Fellow in Allergy & Immunology, Scripps Clinic, La Jolla CA

Bernard A. Feigenbaum, M.D. is a Voluntary Assistant Clinical Professor at UCSD School of Medicine, and was formerly on the clinical faculty at Yale University School of Medicine and NYU School of Medicine. He is Board-Certified, and has over 28 years of clinical and teaching experience as an adult and pediatric Allergy & Immunology specialist.

He attended the Boston University 6-year accelerated medical program and received his B.A. and M.D. in 1989.

Dr. Feigenbaum has given presentations about Professionalism in Medicine for the American Board of Internal Medicine and has lectured extensively at hospitals in NYC including NYU Langone, Memorial Sloan-Kettering, Hospital for Special Surgery. He is the former Director of the NYU Adverse Drug Reaction & Desensitization Program.

Dr. Feigenbaum has been a Principal Investigator at NYU Langone Medical Center, and published a translational study regarding mycotoxins in chronic rhinosinusitis. He has had 17 articles, abstracts and/or letters published regarding allergic contact dermatitis; aspirin-exacerbated respiratory disease (AERD; Samter’s triad); chemotherapy and monoclonal drug desensitization; chronic rhinosinusitis; reflux in asthma; bee sting allergy; vocal cord dysfunction; and nitric oxide in asthma.

He currently serves on several national committees of the American Academy of Allergy, Asthma & Immunology and is a fellow of the American Contact Dermatitis Society.

Dr. Feigenbaum is passionate about improving state-of-the-art Allergy & Immunology medical care and is known for his friendly, caring manner, his professionalism, and his teaching skills.​  

Bernard A. Feigenbaum, M.D. FACP, FAAAAI

Board-Certified, American Board of Allergy & Immunology

​Allergy & Immunology, Internal Medicine

1989 MD Boston University School of Medicine (Accelerated 6 Year Medical Program. Combined BA/MD 1983 to 1989)

Residency & Fellowship
1989-1992 Internal Medicine Intern and Resident, (Scripps) Mercy Hospital
1992-1993 Chief Resident, (Scripps) Mercy Hospital
1993-1995 Clinical Fellow in Allergy & Immunology, Scripps Clinic

1995, 2003--present                  American Board of Allergy & Immunology
2010-present                              California License Registration #G69281

Academic Appointments
1992-1995 Clinical Instructor of Medicine, University of California, San Diego
1996-1999 Clinical Instructor of Medicine, Yale University School of Medicine
1999-2008 Assistant Clinical Professor of Medicine, Yale University School of Medicine
2005-2007 Clinical Assistant Professor of Medicine, NYU School of Medicine
2007-2016 Clinical Assistant Professor of Medicine & Otolaryngology, NYU School of Medicine 

2015-present Voluntary Assistant Clinical Professor, UCSD School of Medicine.